Multiple sclerosis market in the US to Grow by USD 3.95 billion from 2021 to 2026 | Rising prevalence of multiple sclerosis will drive growth -Technavio

NEW YORK, Aug. 25, 2023 /PRNewswire/ — The multiple sclerosis market size in US is expected to increase by USD 3.95 billion from 2021 to 2026, with a CAGR of 5.83% according to the research report by Technavio. request a sample report

Multiple sclerosis market in US Insights –

Companies: 15+, Including Bayer AG, Biogen Inc., Bristol Myers Squibb Co., F. Hoffmann La Roche Ltd., Johnson and Johnson Inc., Novartis AG, Pfizer Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd., and Viatris Inc.
Coverage: Parent market analysis; key drivers, major trends, and challenges; customer and company landscape; company product insights and recent developments; key Companies; and market positioning of Companies
Segments: Type (Biologics and Small molecules), route of administration (parenteral and oral).

To understand more about the Multiple sclerosis market in US, request a sample report

Multiple sclerosis market in US – Company Insights

The growing competition in the market is compelling companies to adopt various growth strategies, such as promotional activities and spending on advertisements to improve the visibility of their services. Technavio report analyzes the market’s competitive landscape and offers information on several market companies, including -Bayer AG, Biogen Inc., Bristol Myers Squibb Co., F. Hoffmann La Roche Ltd., Johnson and Johnson Inc., Novartis AG, Pfizer Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd., and Viatris Inc.

Multiple Sclerosis Market In the US – Market Dynamics

Key Driver – The rising prevalence of multiple sclerosis is the key factor driving the growth of the market.

Leading Trend –

The rising strategic alliance and partnership among players is another factor supporting the multiple sclerosis market growth. Market advocates form strategic partnerships and acquire suppliers to develop products. For example, in 2021, Biogen announced a partnership and licensing agreement with InnoCare Pharma for orelabrutinib, an oral Bruton’s small molecule tyrosine kinase inhibitor (BTKi) for the treatment of MS patients. The partnership will allow Biogen to expand its MS pipeline portfolio with a promising treatment approach. Likewise, in 2020, Mapi Pharma and Mylan deepened their partnership to develop and commercialize the once-monthly Glatiramer Acetate Depot injectable. Mylan has invested USD 20 million to support an ongoing Phase III clinical study aimed at bringing Glatiramer Acetate (GA) Depot to the US market. Thus, such alliances and partnerships among players will drive the growth of the market during the forecast period.

Significant Challenge – The high cost of drugs will be a major challenge for the multiple sclerosis market in the US.

Drivers, and challenges have an impact on market dynamics and can impact businesses. Find some insights from a sample report!

The multiple sclerosis market in US report provides critical information and factual data, with a qualitative and quantitative study of the market based on market drivers and limitations as well as future prospects.

Why Buy?

Add credibility to strategy
Analyzes competitor’s offerings
Get a holistic view of the market

Grow your profit margin with Technavio- Buy the Report

What are the key data covered in this Multiple Sclerosis Market In US report?

CAGR of the market during the forecast period
Detailed information on factors that will drive the growth of the multiple sclerosis market In US between 2022 and 2026
Precise estimation of the multiple sclerosis market In US size and its contribution to the market in focus on the parent market
Accurate predictions about upcoming trends and changes in consumer behavior
Growth of the multiple sclerosis market In US across US
A thorough analysis of the market’s competitive landscape and detailed information about companies
Comprehensive analysis of factors that will challenge the growth of multiple sclerosis market In companies

Gain instant access to 17,000+ market research reports.

Technavio’s SUBSCRIPTION platform

Related Reports:

The amyotrophic lateral sclerosis treatment market size is anticipated to increase to USD 627.17 million from 2021 to 2026, and the market’s growth momentum will accelerate at a CAGR of 12.54%. Furthermore, this report extensively covers amyotrophic lateral sclerosis treatment market segmentation by type (intravenous and oral) and geography (North America, Europe, Asia, and Rest of World (ROW)). The increase in incidence and prevalence of amyotrophic lateral sclerosis is notably driving the amyotrophic lateral sclerosis treatment market growth.

The atherosclerosis therapeutics market size is expected to increase by USD 3.44 billion from 2021 to 2026, and the market’s growth momentum will accelerate at a CAGR of 5.66%. Furthermore, this report extensively covers atherosclerosis therapeutics market segmentation by product (small molecules and biologics) and geography (North America, Europe, Asia, and Rest of World (ROW)). The increasing risk factors for atherosclerosis is one of the key factors supporting the atherosclerosis therapeutics market growth.

Table of Contents

1 Executive Summary

2 Market Landscape

3 Market Sizing

4 Historic Market Size

5 Five Forces Analysis

6 Market Segmentation by Type

7 Market Segmentation by Route of Administration

8 Customer Landscape

9 Geographic Landscape

10 Drivers, Challenges, and Trends

11 Company Landscape

12 Company Analysis

13 Appendix

About US

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact

Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

Email: [email protected]

Website: www.technavio.com